Display options
Cite
Bertucci F, Finetti P, Mamessier E, et al. PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology. 2015;4(5):e1002729doi: 10.1080/2162402X.2014.1002729.
Bertucci, F., Finetti, P., Mamessier, E., Pantaleo, M. A., Astolfi, A., Ostrowski, J., & Birnbaum, D. (2015). PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology, 4(5), e1002729. https://doi.org/10.1080/2162402X.2014.1002729
Bertucci, François, et al. "PDL1 expression is an independent prognostic factor in localized GIST." Oncoimmunology vol. 4,5 (2015): e1002729. doi: https://doi.org/10.1080/2162402X.2014.1002729
Bertucci F, Finetti P, Mamessier E, Pantaleo MA, Astolfi A, Ostrowski J, Birnbaum D. PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology. 2015 Feb 03;4(5):e1002729. doi: 10.1080/2162402X.2014.1002729. eCollection 2015 May. PMID: 26155391; PMCID: PMC4485716.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Feb 03;4(5):e1002729. doi: 10.1080/2162402X.2014.1002729. eCollection 2015 May.

PDL1 expression is an independent prognostic factor in localized GIST.

Oncoimmunology

François Bertucci, Pascal Finetti, Emilie Mamessier, Maria Abbondanza Pantaleo, Annalisa Astolfi, Jerzy Ostrowski, Daniel Birnbaum

Affiliations

  1. Department of Molecular Oncology; Institut Paoli-Calmettes; Centre de Recherche en Cancérologie de Marseille ; UMR1068 Inserm; Marseille, France ; Aix-Marseille University ; Marseille, France ; French Sarcoma Group ; Lyon, France.
  2. Department of Molecular Oncology; Institut Paoli-Calmettes; Centre de Recherche en Cancérologie de Marseille ; UMR1068 Inserm; Marseille, France.
  3. Department of Specialized, Experimental and Diagnostic Medicine; Sant'Orsola-Malpighi Hospital ; Bologna, Italy.
  4. Giorgio Prodi Cancer Research Center; University of Bologna ; Bologna, Italy.
  5. Department of Gastroenterology and Hepatology; Cancer Center-Institute and Medical Center of Postgraduate Education ; Warsaw, Poland.

PMID: 26155391 PMCID: PMC4485716 DOI: 10.1080/2162402X.2014.1002729

Abstract

Gastrointestinal stromal tumors (GIST) are the most frequently occurring digestive sarcomas. The prognosis of localized GIST is heterogeneous, notably for patients with an Armed Forces Institute of Pathology (AFIP) intermediate or high risk of relapse. Despite imatinib effectiveness, it is crucial to develop therapies able to overcome the resistance mechanisms. The immune system represents an attractive prognostic and therapeutic target. The Programmed cell Death 1 (PD1)/programmed cell death ligand 1 (PDL1) pathway is a key inhibitor of the immune response; recently, anti-PD1 and anti-PDL1 drugs showed very promising results in patients with solid tumors. However, PDL1 expression has never been studied in GIST. Our objective was to analyze PDL1 expression in a large series of clinical samples. We analyzed mRNA expression data of 139 operated imatinib-untreated localized GIST profiled using DNA microarrays and searched for correlations with histoclinical features including postoperative metastatic relapse.

Keywords: AFIP, Armed Forces Institute of Pathology; DNA microarray; FDR, false discovery rate; GEO, gene expression omnibus; GES, gene expression signatures; GIST; GIST, gastrointestinal stromal tumors; GO, gene ontology; IHC, immunohistochemistry; ISH, in situ hybridization; MFS, metastasis-free survival; MHC, major histocompatibility complex; NCBI, National Center for Biotechnology Information; NK cells, natural killer cells; PCA, principal component analysis; PD1, programmed cell death 1; PDGFRA, platelet-derived growth factor receptor α; PDL1; PDL1, programmed cell death ligand 1; REMARK, REcommendations for tumor MARKer; RMA, robust multichip average; ROC, receiver operating characteristic; TILs, tumor-infiltrating lymphocytes; Treg, regulatory T cells; WT, wild type; gene expression; immune response; prognosis; qRT-PCR, quantitative reverse transcription-polymerase chain reaction

References

  1. J Clin Invest. 2004 Aug;114(3):379-88 - PubMed
  2. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):638-45 - PubMed
  3. Cancer Lett. 2014 Dec 1;355(1):70-5 - PubMed
  4. Cancer Immunol Res. 2014 Jul;2(7):690-8 - PubMed
  5. Cancer. 2011 May 15;117(10):2192-201 - PubMed
  6. Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6994-9 - PubMed
  7. Cancer Res. 2009 Apr 15;69(8):3563-9 - PubMed
  8. Clin Cancer Res. 2009 Jun 15;15(12):4191-8 - PubMed
  9. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  10. BMC Cancer. 2008 Feb 23;8:57 - PubMed
  11. Nat Rev Clin Oncol. 2011 Mar;8(3):151-60 - PubMed
  12. Lancet Oncol. 2009 Nov;10(11):1045-52 - PubMed
  13. Ann Surg Oncol. 2011 Jun;18(6):1698-704 - PubMed
  14. Am J Surg Pathol. 2011 Nov;35(11):1646-56 - PubMed
  15. Eur J Cancer. 2013 Sep;49(14 ):2965-7 - PubMed
  16. BMC Cancer. 2009 Nov 27;9:413 - PubMed
  17. Ann Surg Oncol. 2013 Feb;20(2):593-9 - PubMed
  18. J Clin Oncol. 2008 Sep 1;26(25):4100-8 - PubMed
  19. Hum Pathol. 2005 Jul;36(7):828-37 - PubMed
  20. Cancer Sci. 2003 Apr;94(4):315-20 - PubMed
  21. Lab Invest. 2010 Sep;90(9):1285-94 - PubMed
  22. PLoS One. 2013 Oct 04;8(10):e77219 - PubMed
  23. Oncoimmunology. 2012 Nov 1;1(8):1223-1225 - PubMed
  24. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 - PubMed
  25. Annu Rev Med. 2012;63:247-58 - PubMed
  26. Clin Cancer Res. 2014 Dec 1;20(23):6105-16 - PubMed
  27. Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70 - PubMed
  28. Cancer Res. 2013 Jun 15;73(12):3499-510 - PubMed
  29. Br J Cancer. 2012 Oct 9;107(8):1433-41 - PubMed
  30. Lancet. 2009 Mar 28;373(9669):1097-104 - PubMed
  31. J Exp Med. 2009 Dec 21;206(13):3015-29 - PubMed
  32. Clin Cancer Res. 2014 May 15;20(10):2773-82 - PubMed
  33. Biostatistics. 2007 Jan;8(1):118-27 - PubMed
  34. Hum Pathol. 2006 Jun;37(6):648-55 - PubMed
  35. Clin Cancer Res. 2012 Feb 1;18(3):826-38 - PubMed
  36. Ann Oncol. 2014 Sep;25 Suppl 3:iii21-6 - PubMed
  37. Mol Cancer. 2011 Jul 21;10:86 - PubMed
  38. Nat Med. 2011 Aug 28;17(9):1094-100 - PubMed
  39. Sci Transl Med. 2013 Aug 28;5(200):200ra116 - PubMed
  40. BMC Genomics. 2006 May 16;7:115 - PubMed
  41. Breast Cancer Res Treat. 2014 Sep;147(2):457-8 - PubMed
  42. Eur J Cancer. 2013 Jun;49(9):2233-42 - PubMed
  43. Int J Cancer. 2010 Aug 15;127(4):899-909 - PubMed
  44. Immunotherapy. 2014;6(4):459-75 - PubMed
  45. Semin Diagn Pathol. 2006 May;23(2):70-83 - PubMed
  46. JAMA. 2012 Mar 28;307(12):1265-72 - PubMed
  47. Cancer Immunol Res. 2013 Jul;1(1):54-63 - PubMed
  48. Nat Rev Cancer. 2011 Nov 17;11(12):865-78 - PubMed
  49. Eur J Gastroenterol Hepatol. 2008 Apr;20(4):327-34 - PubMed
  50. Oncoimmunology. 2013 Dec 1;2(12):e26621 - PubMed
  51. Nat Med. 2011 Jun;17(6):700-7 - PubMed
  52. Eur J Cancer. 2013 Sep;49(14):2968-71 - PubMed
  53. Cancer Immunol Immunother. 2007 May;56(5):739-45 - PubMed
  54. Sci Transl Med. 2011 Nov 30;3(111):111ra120 - PubMed
  55. Lab Invest. 2014 Jan;94(1):107-16 - PubMed
  56. Clin Cancer Res. 2014 Oct 1;20(19):5064-74 - PubMed
  57. Bioinformatics. 2011 Nov 15;27(22):3204-5 - PubMed
  58. J Clin Oncol. 2005 Dec 20;23(36):9067-72 - PubMed
  59. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 - PubMed
  60. PLoS One. 2014 Feb 14;9(2):e88557 - PubMed
  61. Lancet Oncol. 2010 Oct;11(10 ):942-9 - PubMed
  62. J Pathol. 2011 Jan;223(2):251-61 - PubMed
  63. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 - PubMed
  64. Am J Clin Pathol. 2004 Jul;122(1):35-43 - PubMed
  65. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed
  66. Biostatistics. 2003 Apr;4(2):249-64 - PubMed

Publication Types